Study: NCT03034967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danirixin matching placebo
Description: Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.